effective in 12 out of 15 animals when given for three months,'2 and extends previous preliminary results in women with endometriosis." 14 The one patient who did not respond to the treatment had a particularly severe form of the disease and was treated with agonist only once daily. During the course of this and other studies it became apparent that more frequent administration of the agonist might be more effective in maintaining suppression of follicular oestradiol (J Brancroft, R W Shaw, H M Fraser, unpublished findings).
As reported in other studies on the effects of long term treatment with a luteinising hormone releasing hormone agonist for contraception6 8 the return of ovulatory cycles after the end of treatment was not delayed. Indeed, one of the patients who had presented with infertility became pregnant two months after stopping treatment with the agonist.
Although no important side effects of the agonist were reported during the six month treatment regimen, longer term treatment may lead to a degree of oestrogen suppression that results in hot flushes developing in some women, as has been observed in patients receiving agonist treatment for the premenstrual tension syndrome (J Brancroft, R W Shaw, H M Fraser, unpublished findings). It may well be necessary, however, to endeavour to achieve almost total suppression of ovarian function to allow endometriotic lesions to resolve and avoid the problem of prolonged unopposed oestrogen acting on the endometrium. Acne and anticonvulsants R GREENWOOD, P B C FENWICK, W J CUNLIFFE Abstract The severity of acne and rate of excretion of sebum were assessed in 243 patients with epilepsy taking various anticonvulsants who were in hospital long term and in matched controls derived from a normal population of 2176 people. Neither the prevalence of acne nor the sebum excretion rate significantly increased in the patients compared with the controls or in patients taking phenytoin compared with those not.
It is concluded that anticonvulsant treatment does not cause acne.
Introduction
Phenytoin was first made available for the treatment of epilepsy in 1938. Since then, despite a lack of clinical and scientific evidence, it has been widely believed and taught that anticonvulsants, and in particular phenytoin, cause or aggravate acne.' We report the results of a study of patients with epilepsy who were taking anticonvulsants and were in hospital long term. We set out to ascertain whether acne was more prevalent in patients with epilepsy than in the general population. Seborrhoea is cited as being one of the causative factors in acne,2 and we therefore measured the rate of excretion of sebum in a selected number of the patients. We also studied particularly those patients taking phenytoin as this is the drug most commonly linked with acne.
Subjects and methods
We studied 131 men (aged 16-70) and 111 women (aged 17-70). We graded the severity of their acne with a standardised technique with a high degree of interobserver correlation.3 The grades were compared with those assessed in 1077 men (aged 18-69) and 1099 women (aged 18-69) taken from a normal factory population and not receiving any drug.4 Statistical analysis for this comparison was by the x2 method.
The sebum excretion rate was measured in 37 men with epilepsy (mean age 32 (SD 1 67) years) by the gravimetric technique of Strauss and Pochi5 as modified by Cunliffe and Shuster.' Results were compared with the sebum excretion rate in a population of men not taking anticonvulsants but with acne of comparable severity. 6 All the patients with epilepsy were taking at least one anticonvulsant. Exact data on drugs being taken by the women were not available. Of the men, 57 were taking phenytoin with or without other drugs. Other drugs included phenobarbitone, carbamazepine, sodium valproate, primidone, ethosuximide, and clonazepam.
Results
Severity and prevalence of acne- Table I shows the numbers of patients and controls studied, their ages, and the severity of acne. The prevalence and severity of acne in both male and female patients were similar to those in the normal population.
Rate of excretion of sebum-The figure compares sebum excretion rate and severity of acne in the men. There was no significant difference between the group with epilepsy and the normal group at any grade of acne.
Phenytoin- Table II shows the mean severity of acne and the rate of excretion of sebum in men with epilepsy according to whether they were taking phenytoin. There was no significant difference in either variable between the two groups.
Discussion
Phenytoin may cause hirsutism7 8 and has been widely assumed to cause acne.' 8 One case has been reported of a patient whose acne improved dramatically on withdrawal of phenytoin having previously failed to respond to conventional acne treatment. 9 High doses of testosterone increase the sebum excretion rate by 10%o in men and by more in women. Drugs that have an androgenic effect can thus theoretically produce acne. Because of the apparent androgenic effect of phenytoin any increased prevalence in acne has been presumed to be caused by stimulation of the pilosebaceous unit. The results of the study of sebum excretion rates uphold the clinical results, the sebum excretion rate measured being that expected for the severity of the acne. The sebum excretion rate was not increased in the patients taking phenytoin or phenobarbitone. This conflicts with the only other work on sebum excretion rates in such patients, which found a raised sebum excretion rate in patients taking phenobarbitone compared with those receiving promethazine and phenothiazine, the rates in these two groups being those found in a normal population.10
We suggest that it is a myth that anticonvulsants cause acne.
